Search

Your search keyword '"V, Pengo"' showing total 479 results

Search Constraints

Start Over You searched for: Author "V, Pengo" Remove constraint Author: "V, Pengo"
479 results on '"V, Pengo"'

Search Results

1. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

2. The role of platelets in antiphospholipid syndrome

3. Frailty and outcomes in octogenarians with atrial fibrillation treated with edoxaban: ESCAPE study

4. Laboratory diagnosis of antiphospholipid syndrome

5. POS0462 HYDROXYCHLOROQUINE REDUCES THE TITERS OF ANTI-DOMAIN 1 ANTIBODIES OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES: RESULTS FROM THE APS ACTION CLINICAL DATABASE AND REPOSITORY ('REGISTRY')

6. P4671A well-defined subgroup of chronic thromboembolic pulmonary hypertension patients are positive for antiphospholipid antibodies

7. Oral and Poster Presentations

8. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment

9. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis

10. Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study

11. Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation

12. Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study

13. Risk stratification and outcomes in hemodynamically stable patients with acute pulmonary embolism: a prospective, multicentre, cohort study with three months of follow-up

15. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial

16. D-dimer testing to determine the duration of anticoagulation therapy

17. A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants

18. [Thromboembolism in non-rheumatic atrial fibrillation]

19. [Prevention of thromboembolism in non-rheumatic atrial fibrillation: an update]

20. Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment)

21. Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of portable prothrombin time monitor (COAGUCHECK)

23. The management of oral anticoagulant therapy: the patient's point of view

24. Procoagulant effect of anti-beta2-glycoprotein I antibodies with lupus anticoagulant activity

25. dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies

26. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation

27. Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy)

28. Utilization of dilute Russell's viper venom time to detect autoantibodies against beta 2-glycoprotein I which express anticoagulant activity in the presence but not in the absence of exogenous phospholipids

29. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy

30. [Primary pulmonary hypertension and anticoagulant therapy]

31. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when beta 2-glycoprotein I is bound to a suitable surface

32. Immunological specificity and mechanism of action of IgG lupus anticoagulants

34. [Thrombolytic therapy with urokinase in 8 patients with massive pulmonary thromboembolism]

36. [Study of blood platelet activation in migraine in childhood]

38. [Degradation products of fibrinogen in synovial fluid]

42. The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs

43. Impact of the 2023 ACR/EULAR Classification Criteria on START2 Antiphospholipid Registry.

44. Rituximab in lupus anticoagulant hypoprothrombinemia syndrome: A case report.

45. The use of reduced DOAC doses in atrial fibrillation patients does not always lead to good anticoagulation levels and avoid adverse events.

46. Efficacy and safety of low-dose acetylsalicylic acid for the prevention of thromboembolic events in individuals positive for antiphospholipid antibodies: A systematic review and meta-analysis.

47. An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies.

48. The safety of available pharmacotherapy for stroke prevention in atrial fibrillation.

49. ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the APS ACTION Clinical Database and Repository.

Catalog

Books, media, physical & digital resources